IPO News and Updates


Tantech Holdings, a Chinese manufacturer of household bamboo charcoal products, submitted an initial filing and announced terms for its IPO on Tuesday. The Lishui City, China-based company plans to raise $8 million by offering 1.6 million shares at a price range of $4 to $6. At the midpoint of the proposed range, Tantech Holdings would command a market value of $108 million.

Founder, Chairman and CEO Zhengyu Wang will own a 93% post-IPO stake. All but 1.6 million shares are subject to a 180-day lock-up.

Tantech Holdings, which was founded in 2002 and booked $61 million in sales for the 12 months ended December 31, 2013, plans to list on the NASDAQ under the symbol TANH. Tantech Holdings initially filed confidentially on September 30, 2013. Newbridge Securities is the sole bookrunner on the deal.

Keywords: TANH


Civitas Solutions, which provides non-institutional care services for the developmentally disabled, raised $199 million by offering 11.7 million shares at $17, well below the $20 to $23 range. Civitas will list on the NYSE under the symbol CIVI. Barclays, BofA Merrill Lynch and UBS Investment Bank acted as joint bookrunners on the deal.

Keywords: CIVI


Proteon Therapeutics, a biotech developing a recombinant protein for patients undergoing surgery for kidney failure, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering.

Proteon expects its lead product to enter Phase 3 trials in the 1H15, with results expected in 2017. In preparation for hemodialysis, a surgeon must often create an arteriovenous fistula (AVF) to provide vascular access. The company estimates there are 130,000 AVFs created in the US annually, yet these have a greater than 50% failure rate in the first year of placement, and a higher failure rate for radiocephalic AVFs, its initial indication. AVF failure can be restored with a balloon angioplasty, but Proteon claims that surgeons can apply drops of its recombinant human elastase, a type of protein, to prevent complications further on.

Primary shareholders include TVP Capital, Abingworth Bioventures, Prism Venture Partners, Skyline Venture Partners, Deerfield, Pharmstandard, Intersouth, MPM Capital and CEO Timothy Noyes.

Another recombinant protein maker, rEVO Biologics (RBIO), is set to price Tuesday night and begin trading on Wednesday. Two 2014 biotechs focused on kidney failure, Ardelyx (ARDX) and Concert Pharmaceuticals (CNCE), both trade below the IPO price.

The Waltham, MA-based company, which was founded in 2001 and booked n/a in sales for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol PRTO. Proteon Therapeutics initially filed confidentially on June 25, 2014. Stifel and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

Keywords: PRTO, RBIO, Biotech


Live Oak Bancshares, which lends to small businesses in niche industries across the country, withdrew its plans for an initial public offering on Tuesday citing a successful private placement to institutional investors.

Live Oak originally filed for an $86 million IPO in April 2014. At the time of its filing, primary shareholders had included Chairman and CEO James Mahan, William Williams and Neil Underwood.

Unlike Live Oak, most bank IPOs this year have been regional. The group of 9 bank IPOs has averaged a 7% gain from the IPO price, underperforming the broader group. The year's largest finance IPO, Citizen's Financial Group (CFG), is expected to price next week in a deal that could raise over $3 billion.

The Wilmington, NC-based company was founded in 2008 and booked $58 million in revenue for the 12 months ended December 31, 2013. It hand planned to list on the NASDAQ under the symbol LOB. Keefe Bruyette Woods was set to be the sole bookrunner on the deal.

Keywords: LOB

Archived News Headlines
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: IPO investment firm Renaissance Capital (www.renaissancecapital.com).
Performance Disclosure: Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.

As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The Renaissance IPO Index® (IPOUSA) is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE. The S&P 500 index components are determined by S&P Dow Jones Indices.

Risk Disclosure: Investments in the Renaissance IPO ETF, symbol "IPO" (the “ETF”) and the Global IPO Fund, symbol "IPOSX" (the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETF and the Mutual Fund (the “Funds”) invest in companies that have recently completed their initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. The Funds may also be subject to information technology risk and small and mid-capitalization company risk due to a greater number of IPOs in these sectors. The Funds may hold securities in the form of Depository Receipts, REITs, Master Limited Partnerships (MLPs) which have greater risks than common shares. The strategy has high portfolio turnover and securities lending risks. ETF returns may not match the return of the respective index. The ETF is classified as a non-diversified investment company and is subject to concentration risk.

Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with information about the Funds, please visit www.renaissancecapital.com. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETF, 1-866-486-6645.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.